LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Stock List・Cytokinetics Inc

Cytokinetics Inc

Closed

SectorHealthcare

78.75 3.73

Buy Sell

Overview

Share price change

24h

Current

Min

75.97

Max

79.03

Key metrics
By Trading Economics
Income	-23M -206M
Sales	1.6M 19M
EPS	-1.67
Profit margin	-1,064.485
Employees	673
EBITDA	112K -180M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+25.17% upside

Dividends
By Dow Jones
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	2B 10B
Previous open	75.02
Previous close	78.75

News Sentiment

By Acuity

91%

330 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

32.3 / 40.43 Support & Resistance

Cytokinetics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

20 May 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 May 2026, 22:52 UTC

Major Market Movers

Osisko Shares Fall on Planned Convertible Notes Offering

20 May 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 May 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 May 2026, 23:44 UTC

Earnings

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 May 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 May 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 May 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20 May 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 May 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 May 2026, 23:14 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 May 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 May 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 May 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20 May 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20 May 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 May 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 May 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 May 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 May 2026, 22:10 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 May 2026, 22:00 UTC

Earnings

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 May 2026, 21:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 May 2026, 21:27 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 May 2026, 21:20 UTC

Earnings

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 May 2026, 21:19 UTC

Earnings

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 May 2026, 21:18 UTC

Earnings

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 May 2026, 21:17 UTC

Earnings

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 May 2026, 21:17 UTC

Earnings

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 May 2026, 21:17 UTC

Earnings

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 May 2026, 21:16 UTC

Earnings

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Comparison

Price change

Cytokinetics Inc Forecast

Price Target

By TipRanks

25.17% upside

12 Months Forecast

Average 98.6 USD 25.17%

High 140 USD

Low 67 USD

Based on 20 Wall Street analysts offering 12 month price targets forCytokinetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Based on 20 analysts giving stock ratings to Cytokinetics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

32.3 / 40.43Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

330 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.